Sialix Cancer Research focuses on providing cancer susceptibility antibodies and cancer-associated nucleoprotein antibodies, particularly for breast cancer. They also offer innovative diagnostic solutions, including laser-based photodynamic endoscopic diagnosis using 5-aminolevulinic acid for early detection of gastric adenocarcinoma and gastric adenoma. Their market focus includes both clinical diagnostics and research applications, aiming to advance cancer detection and treatment.
Sialix has made significant contributions to the field of cancer research, with their antibodies being utilized in numerous studies published in PubMed. Their products are essential for various lab-based PCR assays and recombinant lab reagents, supporting scientific advancements in oncology. By supplying high-quality monoclonal and polyclonal antibodies, Sialix plays a crucial role in facilitating cutting-edge cancer research and improving diagnostic accuracy.
